Locoregional advanced melanoma poses a complex clinical challenge that requires a multidisciplinary, patient-centered approach. Numerous agents have been studied for their suitability as intralesional therapy in the past decades, but few have successfully completed phase 3 clinical trial testing.
Methods
The relevant medical literature was searched for articles regarding use of intralesional therapies in metastatic melanoma. Therapies with data from phase 2 or higher studies were selected for review. This review also summarizes the mechanisms of action, adverse-event profiles, and clinical data for these agents.
Results
Intralesional therapies demonstrate promising effects in select patients with advanced melanoma. The optimal approach should be individually tailored and consist of a combination of intralesional therapies, regional perfusions, systemic immunotherapies, targeted therapies, and surgery, if necessary.
Conclusions
Due to its relatively good local response rates and tolerable adverse-event profile, intralesional therapy may be a treatment option for select patients with unresectable, locally advanced or metastatic melanoma.
BalchC.M., BuzaidA.C., SoongS.J.Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.J Clin Oncol.2001; 19(16): 3635–3648.
3.
AbbottA.M., ZagerJ.S.Locoregional therapies in melanoma.Surg Clin North Am.2014; 94(5): 1003–15, viii.
4.
SankiA., KamP.C., ThompsonJ.F.Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology.Ann Surg.2007; 245(4): 591–596.
5.
ChaiC.Y., DeneveJ.L., BeasleyG.M.A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities.Ann Surg Oncol.2012; 19(5): 1637–1643.
6.
EricksonC., MillerS.J.Treatment options in melanoma in situ: topical and radiation therapy, excision and Mohs surgery.Int J Dermatol.2010; 49(5): 482–491.
7.
TestoriA., FariesM.B., ThompsonJ.F.Local and intralesional therapy of in-transit melanoma metastases.J Surg Oncol.2011; 104(4): 391–396.
HerseyP., GallagherS.Intralesional immunotherapy for melanoma.J Surg Oncol.2014; 109(4): 320–326.
10.
ColeyW.B.The treatment of malignant tumors by repeated innoculations of erysipelas: with a report of ten original cases. 1893.Clin Orthop Relat Res.1991;(262): 3–11.
11.
HandleyW.S.The pathology of melanotic growths in relation to their operative treatment.Lancet.1907; i: 927–33, 96-1003.
12.
SarnaikA., CragoG., LiuH.Assessment of immune and clinical efficacy after intralesional PV-10 in injected and uninjected metastatic melanoma lesions (abstract).J Clin Oncol.2014; 32(5 suppl): 9028.
13.
RossM.I.Intralesional therapy with PV-10 (rose bengal) for in-transit melanoma.J Surg Oncol.2014; 109(4): 314–319.
14.
Andtbacka, DelmanK.Responses of injected and uninjected lesions to intralesional tal-imogene laherparepvec (T-VEC) in the OPTiM study and the contribution of surgery to response. Presented at: Society of Surgical Oncology Cancer Symposium; Phoenix, Arizona; March 12-15, 2014. Abstract 52.
BedikianA.Y., RichardsJ., KharkevitchD.A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma.Melanoma Res.2010; 20(3): 218–226.
17.
GreenD.S., Bodman-SmithM.D., DalgleishA.G.Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.Br J Dermatol.2007; 156(2): 337–345.
18.
WeideB., DerhovanessianE., PflugfelderA.High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma.Cancer.2010; 116(17): 4139–4146.
19.
StopeckA.T., JonesA., HershE.M.Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.Clin Cancer Res.2001; 7(8): 2285–2291.
20.
ByrneC.M., ThompsonJ.F., JohnstonH.Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy).Melanoma Res.2005; 15(1): 45–51.
21.
StormF.K., SparksF.C., MortonD.L.Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guerin and hyperthermic perfusion.Surg Gynecol Obstet.1979; 149(1): 17–21.
22.
Rodrlguez-CuevasS., Barroso-BravoS., Almanza-EstradaJ.Electrochemotherapy in primary and metastatic skin tumors: phase II trial using intralesional bleomycin.Arch Med Res.2001; 32(4): 273–276.
23.
ThompsonJ.F., AgarwalaS.S., SmithersB.M.Phase 2 study of intralesional PV-10 in refractory metastatic melanoma.Ann Surg Oncol.2015; 22(7): 2135–2142.
24.
RichardsJ., ThompsonJ., AtkinsMB. A controlled, randomized Phase III trial comparing the response to dacarbazine with and without Allovectin-7 in patients with metastatic melanoma [abstract].Proc Am Soc Clin Oncol.2002; 21.
25.
BedikianA.Y., Del VecchioM.Allovectin-7 therapy in metastatic melanoma.Expert Opin Biol Ther.2008; 8(6): 839–44.
26.
StopeckA.T., HershE.M., AkporiayeE.T.Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma.J Clin Oncol.1997; 15(1): 341–349.
27.
GonzalezR., HutchinsL., NemunaitisJ.Phase 2 trial of allovectin-7 in advanced metastatic melanoma.Melanoma Res.2006; 16(6): 521–526.
28.
KarakousisC.P., DouglassH.O.Jr, YeracarisP.M.BCG immunotherapy in patients with malignant melanoma.Arch Surg.1976; 111(6): 716–718.
29.
SeiglerH.F., ShingletonW.W., PickrellK.L.Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma: a clinical assessment.Plast Reconstr Surg.1975; 55(3): 294–298.
30.
RobinsonJ.C.Risks of BCG intralesional therapy: an experience with melanoma.J Surg Oncol.1977; 9(6): 587–593.
31.
MirL.M., GlassL.F., SersaG.Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy.Br J Cancer.1998; 77(12): 2336–2342.
32.
HellerR., JaroszeskiM.J., ReintgenD.S.Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin.Cancer.1998; 83(1): 148–157.
33.
MartyM., GarbayJ.R., GehlJ.Electrochemotherapy - an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study.EJC Suppl.2006; 4(11): 3–13.
34.
RidolfiL., RidolfiR., Ascari-RaccagniA.Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients.J Eur Acad Dermatol Venereol.2001; 15(3): 218–223.
35.
AgarwalaS.S.Intralesional therapy for advanced melanoma: promise and limitation.Curr Opin Oncol.2015; 27(2): 151–156.
36.
BoydK.U., WehrliB.M., TempleC.L.Intra-lesional interleukin-2 for the treatment of in-transit melanoma.J Surg Oncol.2011; 104(7): 711–717.
37.
ThompsonJ.F., HerseyP., WachterE.Chemoablation of metastatic melanoma using intralesional rose bengal.Melanoma Res.2008; 18(6): 405–411.
38.
SenzerN.N., KaufmanH.L., AmatrudaT.Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.J Clin Oncol.2009; 27(34): 5763–5771.
39.
AndtbackaR.H., KaufmanH.L., CollichioF.Talimogene laherparepvec improves durable response rate in patients with advanced melanoma.J Clin Oncol.2015; 33(25): 2780–2788.
40.
PuzanovM.M., AndtbackaR.H., MinorD.R.Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.J Clin Oncol.2014; 32(5 suppl): 9029.
41.
KidnerT.B., MortonD.L., LeeD.J.Combined intralesional Bacille Calmette-Guerin (BCG) and topical imiquimod for in-transit melanoma.J Immunother.2012; 35(9): 716–720.
42.
NabelG.J., GordonD., BishopD.K.Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes.Proc Natl Acad Sci U S A.1996; 93(26): 15388–15393.
43.
NabelG.J., NabelE.G., YangZ.Y.Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans.Proc Natl Acad Sci U S A.1993; 90(23): 11307–11311.
44.
PlautzG.E., YangZ.Y., WuB.Y.Immunotherapy of malignancy by in vivo gene transfer into tumors.Proc Natl Acad Sci U S A.1993; 90(10): 4645–4649.
45.
CohenM.H., ElinR.J., CohenB.J.Hypotension and disseminated intravascular coagulation following intralesional bacillus Calmette-Guerin therapy for locally metastatic melanoma.Cancer Immunol Immunother.1991; 32(5): 315–324.
46.
MaliB., JarmT., SnojM.Antitumor effectiveness of electro-chemotherapy: a systematic review and meta-analysis.Eur J Surg Oncol.2013; 39(1): 4–16.
47.
KaufmanH.L., KimD.W., DeRaffeleG.Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.Ann Surg Oncol.2010; 17(3): 718–730.
48.
SiZ., HerseyP., CoatesA.S.Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF.Melanoma Res.1996; 6(3): 247–255.
49.
AdlerA., SteinJ.A., KedarE.Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study.J Biol Response Mod.1984; 3(5): 491–500.
50.
EklundJ.W., KuzelT.M.A review of recent findings involving interleukin-2-based cancer therapy.Curr Opin Oncol.2004; 16(6): 542–546.
51.
TartourE., MathiotC., FridmanW.H.Current status of interleukin-2 therapy in cancer.Biomed Pharmacother.1992; 46(10): 473–484.
52.
McDermottD., LebbeC., HodiF.S.Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.Cancer Treat Rev.2014; 40(9): 1056–1064.
53.
ByersB.A., Temple-OberleC.F., HurdleV.Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review.J Surg Oncol.2014; 110(6): 770–775.
54.
TartourE., MehtaliM., Sastre-GarauX.Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings.Br J Cancer.2000; 83(11): 1454–1461.
55.
GreenD.S., DalgleishA.G., BelonwuN.Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma.Br J Dermatol.2008; 159(3): 606–614.
56.
DummerR., RochlitzC., VeluT.Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma.Molec Ther.2008; 16(5): 985–994.
57.
GarciaM.S., OnoY., MartinezS.R.Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream.Melanoma Res.2011; 21(3): 235–243.
58.
RadnyP., CaroliU.M., BauerJ.Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.Br J Cancer.2003; 89(9): 1620–1626.
59.
DehesaL.A., Vilar-AlejoJ., Valeron-AlmazanP.Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2. [In Spanish].Act Dermosifiliogr.2009; 100(7): 571–585.
60.
TanC.Y., NeuhausS.J.Novel use of rose bengal (PV-10) in two cases of refractory scalp sarcoma.ANZ J Surg.2013; 83(1-2): 93.
61.
FooteM.C., BurmeisterB.H., ThomasJ.A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series.Melanoma Res.2010; 20(1): 48–51.
62.
ToomeyP., KodumudiK., WeberA.Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer.PloS One.2013; 8(7): e68561.
DamianD.L., ThompsonJ.F.Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone.J Am Acad Dermatol.2007; 56(5): 869–871.
69.
DamianD.L., ThompsonJ.F.Topical diphencyprone immunotherapy for a large primary melanoma on an elderly leg.Am J Clin Dermatol.2011; 12(6): 403–404.
70.
DamianD.L., SawR.P., ThompsonJ.F.Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma.J Surg Oncol.2014; 109(4): 308–313.
71.
BuckleyD.A., Du VivierA.W.The therapeutic use of topical contact sensitizers in benign dermatoses.Br J Dermatol.2001; 145(3): 385–405.
72.
van der SteenP.H., HappleR.Topical immunotherapy of alopecia areata.Dermatol Clin.1993; 11(3): 619–622.
PowellA.M., Russell-JonesR., BarlowR.J.Topical imiquimod immunotherapy in the management of lentigo maligna.Clin Expert Dermatol.2004; 29(1): 15–21.
76.
ShistikG., PrakashA.V., FenskeN.A.Treatment of locally metastatic melanoma: a novel approach.J Drug Dermatol.2007; 6(8): 830–832.
77.
FlorinV., DesmedtE., Vercambre-DarrasS.Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil.Invest New Drugs.2012; 30(4): 1641–1645.
78.
Junkins-HopkinsJ.M.Imiquimod use in the treatment of lentigo maligna.J Am Acad Dermatol.2009; 61(5): 865–867.
